Anal Cancer: The End of the Road for Neoadjuvant Chemoradiotherapy?
- 1 August 2008
- journal article
- editorial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 26 (22), 3669-3671
- https://doi.org/10.1200/jco.2008.18.1651
Abstract
No abstract availableThis publication has 12 references indexed in Scilit:
- Fluorouracil, Mitomycin, and Radiotherapy vs Fluorouracil, Cisplatin, and Radiotherapy for Carcinoma of the Anal CanalJAMA, 2008
- Neoadjuvant Cisplatin Chemotherapy Before Chemoradiation: A Flawed Paradigm?Journal of Clinical Oncology, 2007
- Cisplatin, Fluorouracil, and Docetaxel in Unresectable Head and Neck CancerNew England Journal of Medicine, 2007
- Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck CancerNew England Journal of Medicine, 2007
- Combining Cisplatin and Mitomycin with Radiotherapy in Anal CarcinomaDiseases of the Colon & Rectum, 2007
- ACT II: The Second UK Phase III Anal Cancer TrialClinical Oncology, 2005
- High-dose radiation therapy and neoadjuvant plus concomitant chemotherapy with 5-fluorouracil and cisplatin in patients with locally advanced squamous-cell anal canal cancer: Final results of a phase II studyAnnals Of Oncology, 2001
- Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups.Journal of Clinical Oncology, 1997
- Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycinThe Lancet, 1996
- Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study.Journal of Clinical Oncology, 1996